Sistema de Salut de Catalunya
Institut Català de la Salut
[Pla Juher H, Carbó A] Medical Oncology, Catalan Institute of Oncology, Hospital Universitari Dr. Josep Trueta, Girona, Spain. Precision Oncology Group (OncoGIR-Pro), Institut d’Investigació Biomèdica de Girona (IDIBGI), Girona, Spain. Department of Epidemiology and Cancer Register, Girona, Spain. [Pardo M] Precision Oncology Group (OncoGIR-Pro), Institut d’Investigació Biomèdica de Girona (IDIBGI), Girona, Spain. [Izquierdo ÀJ] Precision Oncology Group (OncoGIR-Pro), Institut d’Investigació Biomèdica de Girona (IDIBGI), Girona, Spain. Hereditary Cancer Program, Catalan Institute of Oncology, IDIBGI, Girona, Spain. Department of Epidemiology and Cancer Register, Girona, Spain. [Darder E] Hereditary Cancer Program, Catalan Institute of Oncology, IDIBGI, Girona, Spain. Department of Epidemiology and Cancer Register, Girona, Spain. [Munté E] Hereditary Cancer Program, Catalan Institute of Oncology, IDIBELL, L’Hospitalet, Barcelona, Spain. [Torres Esquius S, Balmaña J] Servei d’Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain
Vall d'Hebron Barcelona Hospital Campus
2024-04-09T09:52:00Z
2024-04-09T09:52:00Z
2024-04
Endometrial cancer; Hysterectomy; Serous carcinoma
Càncer d'endometri; Histerectomia; Carcinoma serós
Cáncer endometrial; Histerectomía; Carcinoma seroso
Objective To know the risk of endometrial cancer (EC) in a population of women with BRCA 1/2 pathogenic or likely pathogenic variants after risk-reducing salpingo-oophorectomy (RRSO). Methods The study cohort included data from 857 women with BRCA mutations who underwent RRSO visited four hospitals in Catalonia, Spain, from January 1, 1999 to April 30, 2019. Standardized incidence ratio (SIR) of EC was calculated in these patients using data from a regional population-based cancer registry. Results After RRSO, eight cases of EC were identified. Four in BRCA 1 carriers and four in BRCA2 carriers. The expected number of cases of EC was 3.67 cases, with a SIR of 2.18 and a 95% CI (0.93–3.95). Conclusions In our cohort, the risk of EC in BRCA1/2 carriers after RRSO is not greater than expected. Hysterectomy is not routinely recommended for these patients.
Open Access funding provided thanks to the CRUE-CSIC agreement with Springer Nature. This research did not receive any specific grants from funding agencies in the public, commercial, or not-for-profit sectors.
Article
Published version
English
Endometri - Càncer - Epidemiologia; Anomalies cromosòmiques; Endometri - Càncer - Aspectes genètics; Ovariectomia; ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Surgical Procedures, Operative::Endocrine Surgical Procedures::Castration::Ovariectomy::Salpingo-oophorectomy; PHENOMENA AND PROCESSES::Genetic Phenomena::Genetic Variation::Mutation; DISEASES::Neoplasms::Neoplasms by Site::Urogenital Neoplasms::Genital Neoplasms, Female::Uterine Neoplasms::Endometrial Neoplasms; Other subheadings::Other subheadings::Other subheadings::/epidemiology; TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::intervenciones quirúrgicas::procedimientos quirúrgicos endocrinos::castración::ovariectomía::salpingooforectomía; FENÓMENOS Y PROCESOS::fenómenos genéticos::variación genética::mutación; ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias urogenitales::neoplasias de los genitales femeninos::neoplasias uterinas::neoplasias endometriales; Otros calificadores::Otros calificadores::Otros calificadores::/epidemiología
Springer
Clinical and Translational Oncology;26
https://doi.org/10.1007/s12094-023-03312-4
Attribution 4.0 International
http://creativecommons.org/licenses/by/4.0/
Articles científics - HVH [3440]
